Trial Profile
A Rollover Study to Provide Continued Treatment With M6620 (ATRi Transition Rollover Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Berzosertib (Primary) ; Carboplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck KGaA
- 15 Nov 2023 Planned End Date changed from 11 Oct 2023 to 15 Dec 2023.
- 15 Nov 2023 Planned primary completion date changed from 11 Oct 2023 to 15 Dec 2023.
- 20 Apr 2023 Planned End Date changed from 31 Dec 2022 to 11 Oct 2023.